EDITORIAL Therapeutic Controversies
Bibliographic record
Abstract
Several years ago, a group of disgruntled physicians gath-ered in the house of a Vancouver consultant to discuss the future of health care in the province. They were disgrun-tled because the provincial government had announced plans to reorganize the delivery of health care, expanding the bureaucracy and focusing on the whims of consumer opinion instead of maximizing efficiency in the delivery of services. Coincidentally they had rolled back a fee increase for physicians, citing budget constraints. A guest at the gathering was a physician–scientist who had recently been elected to the provincial legislature. His cam-paign had been supported by sectors of the Vancouver medical community with the understanding that his pres-ence in the government of the day (or even the opposition) would benefit the medical community in general and his supporters in particular. But, of course, once the colleague became a member of the legislature, it became clear he would have little influence on the government’s intended reforms. He dutifully supported his party’s plans for cost-containment within all ministerial budgets, but espe-cially that of the Ministry of Health. He did not dispute the Ministry of Health’s inferences that the pharmaceutical industry was an opportunistic, ethically challenged manipu-lator of medical misfortune. Or that misguided prescribing of expensive medications was a significant contributor to rising costs of health care, even if such prescribing might be reducing costs in other areas of care. These inferences were not, by and large, seen as factual by the disgruntled physi-cians. But they did see value in their colleague’s idea of try-ing to rationalize prescribing patterns, so that any rise in Pharmacare costs could not be laid at the feet of wasteful and unthinking prescribers. Directly or indirectly—it is still unclear which—arising from the gathering of disgruntled physicians, the idea of having a therapeutics review body that was independent of both government and the pharmaceutical industry devel-oped. The Therapeutics Initiative was established in 1994 as
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".